Recurrent Ovarian Germ Cell Tumor Completed Phase 1 Trials for Cediranib (DB04849)

IndicationStatusPhase
DBCOND0029793 (Recurrent Ovarian Germ Cell Tumor)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01131234Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsTreatment